Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils

Immunotherapy against alpha-synuclein (α-syn) is a promising novel treatment strategy for Parkinson's disease (PD) and related α-synucleinopathies. We have previously shown that systemic treatment with the monoclonal oligomer/protofibril-selective antibody mAb47 targeting cytotoxic α-syn leads...

Full description

Bibliographic Details

Published in:	Aging Brain
Main Authors:	S. Ekmark-Lewén, A. Aniszewska, A. Molisak, A. Gumucio, V. Lindström, P.J. Kahle, E. Nordström, C. Möller, J. Fälting, L. Lannfelt, J. Bergström, M. Ingelsson
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Subjects:	Oligomer/protofibril-selective antibody Immunotherapy Alpha-synuclein transgenic mice Oligomers Behavioral outcome
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589958923000233